|
CN120208880A
(zh)
*
|
2019-09-12 |
2025-06-27 |
米拉蒂医疗股份有限公司 |
Mta-协同prmt5抑制剂
|
|
EP4304720A1
(en)
*
|
2021-03-11 |
2024-01-17 |
Mirati Therapeutics, Inc. |
Mta-cooperative prmt5 inhibitors
|
|
CN117769421A
(zh)
*
|
2021-04-08 |
2024-03-26 |
米拉蒂医疗股份有限公司 |
使用prmt5抑制剂治疗癌症的组合疗法
|
|
MX2023011856A
(es)
*
|
2021-04-08 |
2024-01-08 |
Mirati Therapeutics Inc |
Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
|
|
JP2024513494A
(ja)
*
|
2021-04-08 |
2024-03-25 |
ミラティ セラピューティクス、インコーポレイテッド |
がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法
|
|
IL308853A
(en)
*
|
2021-06-02 |
2024-01-01 |
Ideaya Biosciences Inc |
Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
|
|
EP4412997A1
(en)
*
|
2021-10-06 |
2024-08-14 |
Mirati Therapeutics, Inc. |
Methods for separation of enantiomers
|
|
CN118251218A
(zh)
|
2021-10-06 |
2024-06-25 |
米拉蒂医疗股份有限公司 |
使用prmt5抑制剂治疗癌症的组合疗法
|
|
KR20240157631A
(ko)
|
2021-11-05 |
2024-11-01 |
미라티 테라퓨틱스, 인크. |
Prmt5 저해제로서 2-아미노 이미다졸 유도체
|
|
EP4442680A4
(en)
*
|
2021-11-30 |
2026-05-06 |
Abbisko Therapeutics Co Ltd |
Pyrazole derivative, its preparation process and its use in medicine
|
|
EP4458812A1
(en)
*
|
2021-12-27 |
2024-11-06 |
Medshine Discovery Inc. |
Pyrazole-1(2h)-phthalazinone compound and application thereof
|
|
CN114315735B
(zh)
*
|
2021-12-29 |
2023-08-01 |
广州中医药大学(广州中医药研究院) |
一种鲁米诺酯化衍生物及其制备方法与应用
|
|
CN116903611A
(zh)
*
|
2022-01-26 |
2023-10-20 |
上海优理惠生医药有限公司 |
一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用
|
|
EP4493555A4
(en)
*
|
2022-03-15 |
2026-03-25 |
Beone Medicines I Gmbh |
4-(AMINOMETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)ISOQUINOLIN-1(2H)-ONE DERIVATIVES USED AS PRMT5 INHIBITORS COOPERATE WITH MTA
|
|
CN118946549A
(zh)
*
|
2022-04-22 |
2024-11-12 |
北京望实智慧科技有限公司 |
稠和哒嗪酮化合物作为prmt5抑制剂
|
|
CN117843634A
(zh)
*
|
2022-05-24 |
2024-04-09 |
上海美悦生物科技发展有限公司 |
Sik抑制剂及其组合物、制备方法和用途
|
|
CN116178347B
(zh)
*
|
2022-06-29 |
2025-07-04 |
苏州浦合医药科技有限公司 |
Prmt5-mta抑制剂
|
|
EP4574816A4
(en)
|
2022-07-07 |
2026-01-14 |
Xizang Haisco Pharmaceutical Co Ltd |
HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND ITS USE
|
|
CN117430596A
(zh)
*
|
2022-07-13 |
2024-01-23 |
上海海和药物研究开发股份有限公司 |
二并环类mat2a抑制剂及其用途
|
|
WO2024022186A1
(zh)
*
|
2022-07-29 |
2024-02-01 |
四川科伦博泰生物医药股份有限公司 |
甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
|
|
WO2024027703A1
(zh)
*
|
2022-08-02 |
2024-02-08 |
上海艾力斯医药科技股份有限公司 |
一种prmt5抑制剂、其制备方法及应用
|
|
WO2024038004A1
(en)
*
|
2022-08-15 |
2024-02-22 |
Astrazeneca Ab |
Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
|
|
KR20250056257A
(ko)
|
2022-09-01 |
2025-04-25 |
미라티 테라퓨틱스, 인크. |
암의 치료를 위한 prmt5 억제제 및 bcl-2 패밀리 억제제를 사용하는 조합 요법
|
|
KR20250108633A
(ko)
*
|
2022-10-25 |
2025-07-15 |
탱고 테라퓨틱스, 인크. |
결정질 형태, 약제학적 조성물 및 이의 사용 방법
|
|
CN120265615A
(zh)
*
|
2022-11-29 |
2025-07-04 |
正大天晴药业集团股份有限公司 |
含有二氢酞嗪的化合物
|
|
WO2024170488A1
(en)
|
2023-02-13 |
2024-08-22 |
Astrazeneca Ab |
Prmt5 inhibitor for use in cancer therapy
|
|
WO2024173218A1
(en)
|
2023-02-13 |
2024-08-22 |
Mirati Therapeutics, Inc. |
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
|
|
US20240270719A1
(en)
|
2023-02-13 |
2024-08-15 |
Mirati Therapeutics, Inc. |
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
|
|
KR20250143848A
(ko)
|
2023-02-13 |
2025-10-02 |
미라티 테라퓨틱스, 인크. |
2-(4-(4-(아미노메틸)-1-옥소-1,2-디히드로프탈라진-6-일)-1-메틸-1h-피라졸-5-일)-4-클로로-6-시클로프로폭시-3-플루오로벤조니트릴의결정질 형태
|
|
KR102818470B1
(ko)
*
|
2023-02-23 |
2025-06-10 |
한양대학교 산학협력단 |
신규한 아미노락톤 유도체 및 이의 신규한 제조방법
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
CN121752566A
(zh)
*
|
2023-06-16 |
2026-03-27 |
中山优理生物医药有限公司 |
一种氨基吡啶类化合物、其制备方法、包含其药物组合物及其应用
|
|
CN121127465A
(zh)
|
2023-07-14 |
2025-12-12 |
江苏亚虹医药科技股份有限公司 |
蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
|
|
IL326348A
(en)
|
2023-08-08 |
2026-04-01 |
Mirati Therapeutics Inc |
Methods and compositions for treating malignant peripheral nerve sheath tumors
|
|
WO2025031468A1
(zh)
|
2023-08-09 |
2025-02-13 |
江苏恒瑞医药股份有限公司 |
杂芳基化合物、其制备方法及其在医药上的应用
|
|
IL327063A
(en)
|
2023-09-15 |
2026-05-01 |
Ideaya Biosciences Inc |
Methods for treating MAT2A-related diseases
|
|
WO2025064286A1
(en)
*
|
2023-09-19 |
2025-03-27 |
Mirati Therapeutics, Inc. |
Stable 4-(aminomethyl)-6-(phenylpyrazolyl)phthalazinone compositions and processes for preparation thereof
|
|
WO2025064750A1
(en)
|
2023-09-20 |
2025-03-27 |
Ideaya Biosciences, Inc. |
Combination therapy with a parg inhibitor
|
|
CN121866246A
(zh)
*
|
2023-09-20 |
2026-04-14 |
西藏海思科制药有限公司 |
一种含氰基的杂环化合物及其用途
|
|
WO2025072544A1
(en)
|
2023-09-27 |
2025-04-03 |
Ideaya Biosciences, Inc. |
Sulfonamino indazole compounds as inhibitors of parg
|
|
WO2025068985A1
(en)
*
|
2023-09-28 |
2025-04-03 |
Beigene Switzerland Gmbh |
1-(1-oxo-1,2-dihydrophthalazin-6-yl)cycloalkyl-1-carboxamide derivatives as mta-cooperative inhibitors of prmt5
|
|
TW202532064A
(zh)
*
|
2023-11-28 |
2025-08-16 |
大陸商正大天晴藥業集團股份有限公司 |
含有雜環二氫酞嗪的化合物
|
|
WO2025180390A1
(zh)
*
|
2024-02-27 |
2025-09-04 |
烨辉医药科技(上海)有限公司 |
具有四环并环结构的mta协同性prmt5抑制剂化合物
|
|
US20250304556A1
(en)
|
2024-04-02 |
2025-10-02 |
Mirati Therapeutics, Inc. |
Processes for preparation of prmt5 inhibitors and intermediates for making the same
|
|
US20250312343A1
(en)
|
2024-04-08 |
2025-10-09 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
|
|
WO2025217007A1
(en)
|
2024-04-08 |
2025-10-16 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
|
|
US20250312351A1
(en)
|
2024-04-08 |
2025-10-09 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
|
|
WO2026082013A1
(zh)
*
|
2024-10-14 |
2026-04-23 |
西藏海思科制药有限公司 |
一种酞嗪酮类prmt5抑制剂及其中间体的制备方法
|